TNDM

Tandem Diabetes Care, Inc. 2013 10-K Summary

Business Context and Reporting Period

Company: Tandem Diabetes Care, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2013
Business Overview: Tandem is a medical device company focused on insulin-dependent diabetes. Its flagship product, the t:slim Insulin Delivery System, is a consumer-focused insulin pump featuring a touchscreen and Micro-Delivery Technology. Commercial sales began in Q3 2012. The company went public via an IPO in November 2013.

Key Financial Metrics (Year Ended Dec 31, 2013)

Units Shipped: Approximately 7,500 pumps as of December 31, 2013.

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 1,072% year-over-year, driven by the expansion of the sales force from 11 to 36 territories and increased market penetration.
• Gross Margin Improvement: The company moved from a negative gross margin of (54%) in 2012 to a positive 21% in 2013 due to manufacturing efficiencies and scale. This margin was reduced by approximately 5% due to costs associated with a voluntary product recall.
• Capital Structure: The company completed an IPO in November 2013, raising approximately $125 million in net proceeds. All convertible preferred stock was converted to common stock. A $30 million term loan with Capital Royalty Partners was drawn in January 2013.
• Operating Expenses: Selling, General, and Administrative (SG&A) expenses nearly doubled to $44.5 million, reflecting the rapid expansion of commercial operations. R&D expenses increased 23% to $11.1 million.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Strategy: Management expects to continue incurring net losses for the next several years as it expands sales, marketing, and R&D. The company plans to scale its sales organization to 60 territories by Q2 2014. Future products in development include t:flex (larger reservoir), t:sensor (integrated CGM), and t:dual (dual-hormone delivery).

Unusual Items:

• Voluntary Recall: In January 2014, the company announced a voluntary recall of select t:slim cartridges due to potential leaking. Direct costs were approximately $1.6 million, with $1.3 million recorded in Q4 2013 and the remainder expected in Q1 2014.
• Warrant Liability: A $9.0 million non-cash charge was recorded in 2013 related to the revaluation of stock warrants prior to the IPO.

Key Risks:

• Profitability: The company has an accumulated deficit of $169.2 million and cannot assure it will achieve profitability.
• Reimbursement: Sales depend heavily on third-party payor contracts. Medicare competitive bidding processes create uncertainty regarding future reimbursement rates.
• Competition: The market is dominated by larger competitors (e.g., Medtronic, Animas) with greater resources and established relationships.
• Regulatory: Future products (t:sensor) require PMA approval, a lengthy and uncertain process.

Investor Verification Checklist

• Recall Impact: Verify the final financial impact and customer retention rates following the January 2014 cartridge recall.
• Reimbursement Rates: Monitor the status of contracts with third-party payors and the impact of Medicare competitive bidding on pricing power.
• Debt Covenants: Review compliance with the Capital Royalty Partners term loan covenants, specifically the minimum revenue requirements ($25M in 2013, $50M in 2014).
• Product Pipeline: Track regulatory submission timelines for t:flex (510(k)) and t:sensor (PMA) to assess future revenue diversification.
• Burn Rate: Assess the runway of the $124.4 million cash balance against the projected increase in operating expenses required to scale the sales force.